After an eight-year odyssey, the first cytidine triphosphate synthase 1 (CTPS1) inhibitor has entered the clinic, with Step Pharma SAS announcing it has simultaneously begun studies in the U.S. and the U.K. The phase I/II trial is assessing Step’s lead program, STP-938, in relapsed/refractory B- and T-cell lymphomas, with the first U.S. site opening for enrollment this week.
Qu Biologics has received clearance from Health Canada to proceed with a randomized, placebo-controlled trial of QBKPN, a first-in-class innate immune modulator that enhances lung immunity, in the elderly.
Microbiome specialist Enterome SA has out-licensed its lead human hormone mimetic, EM-1010, to Nestlé Health Sciences SA, in a deal that underlines the potential of its approach to generating novel drugs from proteins expressed by gut bacteria. EM-1010, the first program derived from Enterome’s Endomimics platform, is an orally available molecule that acts by promoting local release of interleukin 10 in the gut, with the aim of reducing inflammation. It is in development for the treatment of inflammatory bowel disease and food allergies and due to enter clinical trials in 2023.
RSS
